GSA Capital Partners LLP Has $715,000 Position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Key Points

• GSA Capital Partners LLP increased its holdings in Aurinia Pharmaceuticals by 656.2% during the 1st quarter, owning approximately 0.07% of the company worth $715,000 after acquiring an additional 77,153 shares.
• Aurinia Pharmaceuticals reported a $0.16 EPS for the last quarter, missing analysts' consensus estimates, but had revenue of $70.01 million, exceeding expectations of $64.27 million.
• Brokerage firms have issued various ratings, with HC Wainwright maintaining a "buy" rating and a price target of $17.00, while Royal Bank of Canada raised its price target from $8.00 to $9.00.

GSA Capital Partners LLP lifted its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 656.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,911 shares of the biotechnology company's stock after purchasing an additional 77,153 shares during the quarter. GSA Capital Partners LLP owned approximately 0.07% of Aurinia Pharmaceuticals worth $715,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in AUPH. Raymond James Financial Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at approximately $215,000. American Century Companies Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 124.2% in the 4th quarter. American Century Companies Inc. now owns 171,590 shares of the biotechnology company's stock valued at $1,541,000 after buying an additional 95,066 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $201,000. LPL Financial LLC increased its stake in Aurinia Pharmaceuticals by 21.8% in the 4th quarter. LPL Financial LLC now owns 46,600 shares of the biotechnology company's stock valued at $418,000 after purchasing an additional 8,327 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Aurinia Pharmaceuticals by 6.9% in the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock valued at $15,535,000 after purchasing an additional 112,113 shares in the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Kevin Tang bought 200,000 shares of Aurinia Pharmaceuticals stock in a transaction on Tuesday, August 5th. The shares were bought at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the acquisition, the director directly owned 11,329,500 shares in the company, valued at approximately $132,328,560. This represents a 1.80% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought 1,300,000 shares of company stock worth $13,590,000 over the last 90 days. 12.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on AUPH. Royal Bank Of Canada raised their price objective on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th.

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock traded down $0.27 during mid-day trading on Wednesday, hitting $11.43. 2,613,025 shares of the company were exchanged, compared to its average volume of 1,580,676. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The business's 50 day simple moving average is $8.49 and its two-hundred day simple moving average is $8.18. The company has a market capitalization of $1.50 billion, a P/E ratio of 26.61 and a beta of 1.23. Aurinia Pharmaceuticals Inc has a 12-month low of $5.25 and a 12-month high of $11.80.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $70.01 million during the quarter, compared to analysts' expectations of $64.27 million. Analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.